Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

CRDF Cardiff Oncology Inc

3,905

0,00 (0,00%)

09 Jan 2025 - Geschlossen

Verzögert um 15 Minuten

Annual Report to Security Holders (ars)

This regulatory filing also includes additional resources:
crdf2022ars.pdf

Cardiff Oncology (NASDAQ:CRDF)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Cardiff Oncology Charts.

Cardiff Oncology (NASDAQ:CRDF)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Cardiff Oncology Charts.

News Cardiff Oncology, Inc.

Form 8-K - Current report
Montag 6 Januar 2025 (3 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 18 Dezember 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Dienstag 17 Dezember 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Montag 16 Dezember 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 10 Dezember 2024 (4 Wochen vor) • Edgar (US Regulatory)

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
Dienstag 10 Dezember 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 8-K - Current report
Dienstag 10 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
Dienstag 10 Dezember 2024 (1 Monat vor) • GlobeNewswire Inc.

Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
Dienstag 19 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
Donnerstag 7 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 7 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
Mittwoch 30 Oktober 2024 (2 Monate vor) • GlobeNewswire Inc.

Weitere Cardiff Oncology, Inc. News-Artikel

Financial Select Sector

Invesco QQQ Trust Series 1

Gold vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen